

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Marken James G.</u>			2. Issuer Name and Ticker or Trading Symbol <u>ANI PHARMACEUTICALS INC [ ANIP ]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ <input checked="" type="checkbox"/> Officer (give title below) _____ Other (specify below) _____ <b>SVP OPS &amp; PROD DEV</b>		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <u>06/07/2024</u>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
C/O ANI PHARMACEUTICALS, INC. 210 MAIN STREET WEST			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street)	BAUDETTE MN 56623		Rule 10b5-1(c) Transaction Indication					
(City)	(State)	(Zip)	<input type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.					

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/07/2024		M		7,250	A	\$49.51	123,616 <sup>(1)</sup>	D	
Common Stock	06/07/2024		M		5,300	A	\$57.06	128,916	D	
Common Stock	06/07/2024		F		11,087	D	\$67.7 <sup>(2)</sup>	117,829	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					
Stock Option (right to buy)	\$49.51	06/07/2024		M		7,250	(3)	03/30/2027	Common Stock	7,250	\$49.51	0	D	
Stock Option (right to buy)	\$57.06	06/07/2024		M		5,300	(4)	04/05/2028	Common Stock	5,300	\$57.06	0	D	

**Explanation of Responses:**

- The number of shares beneficially owned by the reporting person is amended in this Form 4 to correct an administrative error in a Form 4 filed on March 9, 2023, which misreported that 1,951 shares were withheld on March 7, 2023 to cover taxes on a vesting of shares on that date, when 1,591 shares were withheld. In correcting this administrative error, the number of shares beneficially owned by the reporting person reflects an increase of 360 shares.
- The shares were sold in multiple trades at prices ranging from \$67.64 to \$68.10. The price reported above reflects the weighted average sales price.
- 25% of the total options vested on each of March 31, 2018, March 31, 2019, March 31, 2020, and March 31, 2021.
- 25% of the total options vested on each of April 6, 2019, April 6, 2020, April 6, 2021, and April 6, 2022.

**Remarks:**

/s/ James G. Marken, by  
attorney-in-fact Meredith W. Cook 06/11/2024

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.